Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.
Atalanta missed out on an automatic place in the Champions League last 16 as they were held to a 2-2 draw at Barcelona on Wednesday. Last season’s Europa League winners, who were missing Ademola ...